
CLAIMS

1. A compound represented by


(1) the formula (I):



(I)

or

(2) the formula (II):



(II)

wherein

R^1 is a C_{1-6} ~~hydrogen atom, an~~ alkyl group ~~optionally having substituent(s), an alkenyl group optionally having substituent(s) or a cycloalkyl group optionally having substituent(s)~~;

R^2 is~~:~~

(1) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from

(a) a hydroxy group,

(b) a halogen atom,

(c) a C_{1-6} alkoxy group,

(d) a C_{1-6} alkyl-carbonyloxy group,

(e) a 4- to 10-membered monocyclic aromatic heterocyclic group

optionally having 1 to 3 halogen atoms,

(f) a C_{3-10} cycloalkyl group, and

(g) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,

(2) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,

(3) a carboxy group,

(4) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group,

(5) a C_{1-6} alkyl-carbonyl group, or

(6) a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from halogen atom(s)~~a halogen atom, a hydroxy group, a cyano (nitrile) group, an amino group optionally having substituent(s), a mercapto group optionally having a substituent (the mercapto group is optionally oxidized), an alkyl group optionally having substituent(s) other than a substituted amino group, an alkoxy group optionally having substituent(s), a 3- to 10-membered cyclic hydrocarbon group optionally having substituent(s), a 3- to 10-membered heterocyclic group optionally having substituent(s) or an acyl group (wherein when the acyl group is -CONR'R", then R' and R" are both hydrogen atoms or form, together with the nitrogen atom bonded thereto, a nitrogen-containing heterocycle optionally having substituent(s))~~;

X is

(1) a hydrogen atom;

(2) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a hydroxy group,

(c) a C_{1-6} alkoxy group optionally having a C_{1-6} alkoxy group or a halogen atom,

(d) a C_{1-6} alkylthio group,

(e) a C_{6-14} aryl group,

(f) a C_{6-14} aryloxy group optionally having a C_{1-6} alkoxy group or a halogen atom, and

(g) a 4- to 10-membered monocyclic aromatic heterocyclic group; or

(3) a C_{3-10} cycloalkyl group~~absent, or a hydrogen atom, an alkyl group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s) or a cycloalkyl group optionally having substituent(s)~~; and

ring A is

(1) ~~a monocyclic heterocycle, optionally having substituent(s),~~


~~selected from pyrimidine, pyrrole, imidazole, pyrazole or~~ triazole optionally further having 1 to 5 substituents selected from substituent group A,

(2)

~~a fused heterocycle, optionally having substituent(s), selected from 1H-pyrrolo[1,2-b]pyridine, 3H-imidazo[4,5-b]pyridine,~~ imidazo[1,2-a]pyridine optionally further having 1 to 5 substituents selected from substituent group A~~, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine, 4,5,6,7-tetrahydro-1H-indole, 4,5,6,7-tetrahydro-1H-benzimidazole, 1,4-dihydrocyclopenta[b]pyrrole, 1,4-dihydropyrrolo[3,2-b]pyrrole, 4H-furo[3,2-b]pyrrole, 4H-thieno[3,2-b]pyrrole, 1,4-dihydrocyclopentaimidazole, 1,4-dihydropyrrolo[2,3-d]imidazole, 1H-furo[2,3-d]imidazole, 1H-thieno[2,3-d]imidazole, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyrazine, imidazo[1,2-c]pyrimidine, imidazo[1,2-b]pyridazine, benzofuran, benzothiophene, or benzothiazole~~, or

(3)

a ring represented by




wherein R^a and R^b are each independently a hydrogen atom, a halogen atom, a C_{1-6} alkoxy group, or a C_{1-6} alkoxy-carbonyl group, and at least one of R^a and R^b is not a hydrogen atom; and Y^1 is N, and Y^2 is CH~~benzimidazole having substituent(s);~~

~~,~~

~~or a salt thereof.~~

~~2. A compound represented by the formula (II):~~



~~wherein~~

~~R^1 is a hydrogen atom, an alkyl group optionally having substituent(s), an alkenyl group optionally having substituent(s) or a cycloalkyl group optionally having substituent(s);~~

R^3 is

(1) a C_{1-6} alkoxy group optionally substituted by a C_{1-6} alkoxy group or a halogen atom,

(2) a C_{1-6} alkylthio group,

(3) a C_{3-10} cycloalkyl group optionally substituted by a C_{1-6} alkyl group,

(4) a C_{6-14} aryl group, or

(5) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally substituted by a C_{1-6} alkyl group~~an alkyl group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s), an alkenyl group optionally having substituent(s), a cycloalkyl~~

~~group optionally having substituent(s), an alkylthio group optionally having substituent(s), an alkylsulfinyl group optionally having substituent(s), an alkylsulfonyl group optionally having substituent(s), an alkoxy group optionally having substituent(s), an aryl group optionally having substituent(s) or a heteroaryl group optionally having substituent(s)~~;

X^1 is a C_{1-6} alkylene group ~~optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s)~~;

ring A^1 is


(1) imidazo[1,2-a]pyridine optionally further having 1 to 5 substituents selected from substituent group A,

(2) indole


~~a fused heterocycle~~ optionally further having 1 to 5 substituent~~(~~s selected from substituent group A, or

(3) benzimidazole optionally further having 1 to 5 substituents selected from substituent group A~~)~~;

the group represented by the formula:



is a group represented by the formula:



wherein R^4 is

(1) a hydrogen atom,

(2) a cyano group,

(3) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from

(a) a hydroxy group,

(b) a C_{1-6} alkoxy group,

(c) a C_{1-6} alkyl-carbonyloxy group,

(d) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 halogen atoms,

(e) a C_{3-10} cycloalkyl group, and

(f) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,

(4) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,

(5) a carboxy group,

(6) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group, or

(7) a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from halogen atom(s)~~ring B is a 5- to 7-membered nitrogen-containing heterocycle optionally having substituent(s)~~; ~~and~~

~~n is 0, 1 or 2,~~

the substituent group A consists of

(1) a halogen atom;

(2) a nitro group;

(3) a cyano group;

(4) a hydroxy group;

(5) a C_{1-6} alkoxy group optionally having 1 to 5 substituents selected from substituent group B;

(6) an amino group optionally having 1 or 2 substituents selected from substituent group B;

(7) oxo group;

(8) thioxo group;

(9) a mercapto group optionally having a substituent selected from substituent group B (the mercapto group is optionally oxidized);
(10) a C_{1-4} alkylenedioxy group;
(11) a C_{1-6} alkyl group optionally having 1 to 5 substituents selected from substituent group B;
(12) a C_{7-16} aralkyl group;
(13) a 3- to 10-membered cyclic hydrocarbon group optionally having 1 to 5 substituents selected from substituent group B; and
(14) a 3- to 10-membered heterocyclic group optionally having 1 to 5 substituents selected from substituent group B; and

the substituent group B consists of
(1) a halogen atom;
(2) a nitro group;
(3) a cyano group;
(4) a hydroxy group;
(5) a C_{1-6} alkoxy group optionally having 1 to 3 halogen atoms;
(6) an amino group;
(7) a mono- or di-C_{1-6} alkylamino group;
(8) a C_{7-16} aralkylamino group;
(9) a C_{1-6} alkoxy-carbonylamino group;
(10) a C_{1-6} alkyl-carbonylamino group;
(11) a C_{1-6} alkyl-carbonyloxy group;
(12) a C_{1-6} alkyl-carbonyl group;
(13) a carboxy group;
(14) a C_{1-6} alkoxy-carbonyl group;
(15) a carbamoyl group;
(16) a mono- or di-C_{1-6} alkylcarbamoyl group;
(17) oxo group;
(18) thioxo group;
(19) a mercapto group;
(20) a C_{1-6} alkylthio group;
(21) a C_{1-6} alkylsulfinyl group;
(22) a C_{1-6} alkylsulfonyl group;
(23) a C_{1-4} alkylenedioxy group;

(24) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from

(a) a halogen atom,

(b) a hydroxy group,

(c) a C_{1-6} alkoxy group,

(d) a C_{6-14} aryl group,

(e) an amino group,

(f) a mono- or di-C_{1-6} alkylamino group,

(g) a C_{7-16} aralkylamino group, and

(h) a C_{1-6} alkoxy-carbonylamino group;

(25) a C_{6-14} aryl group optionally having 1 to 3 halogen atoms;

(26) a 4- to 10-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 halogen atoms ;

(27) a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group;


(28) a C_{7-16} aralkyl group;

(29) a C_{3-10} cycloalkyl group; and


(30) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is optionally having an oxo group,

or a salt thereof.

~~3~~2. The compound of claim ~~2~~1, wherein ~~ring B~~the group represented by the formula:



~~-~~is a group~~ring~~ represented by the formula:



wherein R^4 is

(1) a cyano ~~(nitrile)~~ group,

(2) a C_{1-6} alkyl group optionally having 1 to 3 substituents selected from

(a) a hydroxy group,

(b) a C_{1-6} alkoxy group,

(c) a C_{1-6} alkyl-carbonyloxy group,


(d) a 4- to 10-membered monocyclic aromatic heterocyclic group ~~an aromatic heterocyclic group~~ optionally having 1 to 3 halogen atoms,

(e) a C_{3-10} cycloalkyl group, and


(f) pyrrolidinyl, piperidino, morpholino, thiomorpholino, piperazinyl, imidazolidin-1-yl and pyrazolidin-1-yl, each of which is ~~a cyclic amino group~~ optionally having an oxo group,

(3) a 3- to 10-membered heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group,
(4) a carboxy group,
(5) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group~~a nonaromatic heterocyclic group~~ optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and an oxo group or
(6) a group represented by the formula: -CO-NR'R"
wherein R' and R" are each a hydrogen atom, or
R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle~~a nitrogen-containing heterocycle~~ optionally having 1 to 3 substituents selected from halogen atom(s).

~~4~~3. The compound of claim ~~2~~1, wherein the group represented by the formula:



~~ring B~~ is a group~~ring~~ represented by the formula:



wherein R^4 is a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle~~a nitrogen-containing heterocycle~~ optionally having 1 to 3 substituents selected from halogen atom(s).

~~5. The compound of claim 1 or 2, wherein R^1 is a C_{1-6} alkyl group optionally having substituent(s).~~

~~6~~4. The compound of claim 1, wherein R^2 is

(1) a carboxy group,

(2) a C_{1-6} alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a 3- to 10-membered monocyclic non-aromatic heterocyclic group optionally having 1 to 3 substituents selected from a C_{1-6} alkyl group and oxo group,

(3) a C_{1-6} alkyl-carbonyl group, or

(4) a group represented by the formula: -CO-NR'R" wherein R' and R" are each a hydrogen atom, or R' and R" form, together with the nitrogen atom bonded thereto, a 4- to 7-membered nonaromatic nitrogen-containing heterocycle optionally having 1 to 3 substituents selected from halogen atom(s)~~an acyl group (wherein when the acyl group is -CONR'R", then R' and R" are both hydrogen atoms or form, together with the nitrogen atom bonded thereto, a nitrogen-containing heterocycle optionally having substituent(s))~~.

~~7~~5. The compound of claim 1, wherein X is a C_{1-6} alkyl group optionally substituted by a C_{1-6} alkoxy group.

~~8. The compound of claim 2, wherein X^1 is a C_{1-6} alkylene group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s) and an oxo group.~~

~~9. The compound of claim 2, wherein X^1 is a C_{1-6} alkylene group.~~

~~10~~6. The compound of claim ~~2~~1, wherein R^3 is a C_{1-6} alkoxy group optionally substituted by a C_{1-6} alkoxy group or a halogen atom~~having substituent(s)~~.

~~11~~7. The compound of claim 1, which is 1-(2-f~~F~~luorophenyl)-5-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1H-1,2,3-triazole-4-carboxamide or a salt thereof.

~~12~~8. A medicament comprising the compound of claim 1~~ or 2~~, or a salt thereof as an active ingredient.

~~13~~9. The medicament of claim 8~~12~~, which is a renin inhibitor.

~~14~~10. The medicament of claim 8~~12~~, which is a prophylactic or therapeutic agent of a circulatory disease.


~~15~~11. The medicament of claim ~~12~~8, which is a prophylactic or therapeutic agent of hypertension and/or various organ damages attributable to hypertension.

~~16~~12. Use of the compound of claim 1~~ or 2~~ or a salt thereof for the production of a prophylactic or therapeutic agent for a circulatory disease.

~~17~~13. Use of the compound of claim ~~1~~12, which is ~~or 2 or a salt thereof~~ for the production of a prophylactic or therapeutic agent for

hypertension and/or various organ damages attributable to hypertension.

~~18~~14. Use of the compound of claim 12, which is ~~Use of the compound represented by the formula (I):~~



(I)

~~wherein~~


~~R^1 is a hydrogen atom, an alkyl group optionally having substituent(s), an alkenyl group optionally having substituent(s) or a cycloalkyl group optionally having substituent(s);~~

~~R^2 is a halogen atom, a hydroxy group, a cyano (nitrile) group, an amino group optionally having substituent(s), a mercapto group optionally having a substituent (the mercapto group is optionally oxidized), an alkyl group optionally having substituent(s) other than a substituted amino group, an alkoxy group optionally having substituent(s), a 3- to 10-membered cyclic hydrocarbon group optionally having substituent(s), a 3- to 10-membered heterocyclic group optionally having substituent(s) or an acyl group (wherein when the acyl group is -CONR'R", then R' and R" are both hydrogen atoms or form, together with the nitrogen atom bonded thereto, a nitrogen-containing heterocycle optionally having substituent(s));~~

~~X is absent, or a hydrogen atom, an alkyl group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s) or a cycloalkyl group optionally having substituent(s); and~~


~~ring A is a heterocycle optionally having substituent(s),~~

~~which is other than~~



and

~~wherein ring C is a heterocycle optionally having substituent(s), ring D is a benzene ring optionally having substituent(s), R''' is a substituted alkyl group or a substituted alkoxy group, R'''' is a substituent, and X is as defined above), or represented by the formula (II):~~



(II)

~~wherein~~

~~R^1 is a hydrogen atom, an alkyl group optionally having substituent(s), an alkenyl group optionally having~~

~~substituent(s) or a cycloalkyl group optionally having substituent(s);~~

~~R^3 is an alkyl group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s), an alkenyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), an alkylthio group optionally having substituent(s), an alkylsulfinyl group optionally having substituent(s), an alkylsulfonyl group optionally having substituent(s), an alkoxy group optionally having substituent(s), an aryl group optionally having substituent(s) or a heteroaryl group optionally having substituent(s);~~

~~X^1 is a C_{1-6} alkylene group optionally substituted by group(s) other than a heterospiro ring optionally having substituent(s);~~

~~ring A^1 is a fused heterocycle optionally having substituent(s);~~

~~ring B is a 5- to 7-membered nitrogen-containing heterocycle optionally having substituent(s); and~~

~~n is 0, 1 or 2,~~

~~or a salt thereof,~~

for the production of a prophylactic or therapeutic agent for blood pressure circadian rhythm abnormality, heart disease, progression of cardiac insufficiency after myocardial infarction, or renal disease in medicine.

~~19~~15. Use of the compound of claim ~~18~~14, wherein the heart disease is acute heart failure.

~~20~~16. Use of the compound of claim ~~18~~14, wherein the renal disease is renal failure.